{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T17:23:30Z","timestamp":1794590610602,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T00:00:00Z","timestamp":1614988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Interstitial lung disease is a common complication of systemic sclerosis (SSc-ILD), and it remains difficult to accurately predict its course. Progressing ILD could be more metabolically active, suggesting that the <jats:sup>18<\/jats:sup>F-FDG tracer could be a tool in the managing of SSc-ILD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In our center, SSc patients and controls (non-Hodgkin lymphoma cured after first-line regimen) who had received a PET\/CT were screened retrospectively. The FDG uptake (visual intensity, pattern, SUV<jats:sub>max<\/jats:sub>) was systematically recorded in &gt;\u200930 regions of interest (ROIs) linked to SSc in a blind reviewing by 2 independent nuclear medicine physicians using a standardized form.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the 545 SSc patients followed up in our center, 36, including 22 SSc-ILDs, had a PET\/CT, whose indication was cancer screening in most cases. The mean\u2009\u00b1\u2009SD age was 57.9\u2009\u00b1\u200913.0\u2009years with 20\/36 females. Fourteen patients had a disease duration of less than 2\u2009years. A third had anti-centromere antibodies and 27.8% had anti-topoisomerase antibodies. Pulmonary FDG uptakes were higher in SSc patients than in controls (<jats:italic>n<\/jats:italic>\u2009=\u200989), especially in those with ILD compared with those without ILD. Pulmonary FDG uptakes were positively correlated with the ILD severity (fibrosis extent, %FVC, and %D<jats:sub>LCO<\/jats:sub>). No significant difference was found in the FDG uptakes from extrathoracic ROIs. Progressing SSc-ILDs within the 2\u2009years after PET\/CT (<jats:italic>n<\/jats:italic>\u2009=\u20099) had significant higher pulmonary FDG uptakes at baseline than stable SSc-ILDs (<jats:italic>n<\/jats:italic>\u2009=\u200913).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>PET\/CT could be a useful tool in the assessment of the severity and the prediction of pulmonary function outcome of SSc-ILD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02460-8","type":"journal-article","created":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T03:02:42Z","timestamp":1614999762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["18F-FDG positron emission tomography scanning in systemic sclerosis-associated interstitial lung disease: a pilot study"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3925-9541","authenticated-orcid":false,"given":"Emmanuel","family":"Ledoult","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Morelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Soussan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e8ne","family":"M\u00e9kinian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"B\u00e9hal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Sobanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Huglo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Le Gouellec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Remy-Jardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clio","family":"Baillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,6]]},"reference":[{"issue":"2","key":"2460_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s12016-010-8198-y","volume":"40","author":"E Hachulla","year":"2011","unstructured":"Hachulla E, Launay D. Diagnosis and classification of systemic sclerosis. Clin Rev Allergy Immunol. 2011;40(2):78\u201383. https:\/\/doi.org\/10.1007\/s12016-010-8198-y.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"2","key":"2460_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12016-009-8194-2","volume":"40","author":"J Le Pavec","year":"2011","unstructured":"Le Pavec J, Launay D, Mathai SC, Hassoun PM, Humbert M. Scleroderma lung disease. Clin Rev Allergy Immunol. 2011;40(2):104\u201316. https:\/\/doi.org\/10.1007\/s12016-009-8194-2.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"7","key":"2460_CR3","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(7):940\u20134.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2460_CR4","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13075-019-1867-1","volume":"21","author":"MR Pokeerbux","year":"2019","unstructured":"Pokeerbux MR, Giovannelli J, Dauchet L, Mouthon L, Agard C, Lega J-C, et al. Survival and prognosis factors in systemic sclerosis: data of a French multicenter cohort, systematic review, and meta-analysis of the literature. Arthritis Res Ther. 2019;21(1):86. https:\/\/doi.org\/10.1186\/s13075-019-1867-1.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"2460_CR5","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1164\/rccm.2106012","volume":"165","author":"D Bouros","year":"2002","unstructured":"Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165(12):1581\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"2460_CR6","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1002\/art.39166","volume":"67","author":"AM Hoffmann Vold","year":"2015","unstructured":"Hoffmann Vold AM, Aal\u00f8kken TM, Lund MB, Garen T, Midtvedt \u00d8, Brunborg C, et al. Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis Rheumatol. 2015;67(8):2205\u201312. https:\/\/doi.org\/10.1002\/art.39166.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"2460_CR7","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/rheumatology\/kev016","volume":"54","author":"A Man","year":"2015","unstructured":"Man A, Davidyock T, Ferguson LT, Ieong M, Zhang Y, Simms RW. Changes in forced vital capacity over time in systemic sclerosis: application of group-based trajectory modelling. Rheumatology (Oxford). 2015;54(8):1464\u201371. https:\/\/doi.org\/10.1093\/rheumatology\/kev016.","journal-title":"Rheumatology (Oxford)"},{"key":"2460_CR8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.2147\/OARRR.S226695","volume":"11","author":"A Fischer","year":"2019","unstructured":"Fischer A, Patel NM, Volkmann ER. Interstitial lung disease in systemic sclerosis: focus on early detection and intervention. Open Access Rheumatol. 2019;11:283\u2013307. https:\/\/doi.org\/10.2147\/OARRR.S226695.","journal-title":"Open Access Rheumatol"},{"issue":"12","key":"2460_CR9","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1002\/art.22204","volume":"54","author":"RK Hoyles","year":"2006","unstructured":"Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NSL, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54(12):3962\u201370.","journal-title":"Arthritis Rheum"},{"issue":"25","key":"2460_CR10","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655\u201366.","journal-title":"N Engl J Med"},{"issue":"7","key":"2460_CR11","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1002\/art.40114","volume":"69","author":"ER Volkmann","year":"2017","unstructured":"Volkmann ER, Tashkin DP, Li N, Roth MD, Khanna D, Hoffmann Vold AM, et al. Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II. Arthritis Rheumatol. 2017;69(7):1451\u201360. https:\/\/doi.org\/10.1002\/art.40114.","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"2460_CR12","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327\u201339. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209909.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2460_CR13","first-page":"1064","volume":"35","author":"A B\u00e9rezn\u00e9","year":"2008","unstructured":"B\u00e9rezn\u00e9 A, Ranque B, Valeyre D, Brauner M, Allanore Y, Launay D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol. 2008;35(6):1064\u201372.","journal-title":"J Rheumatol"},{"issue":"2","key":"2460_CR14","doi-asserted-by":"publisher","first-page":"234","DOI":"10.5301\/jsrd.5000205","volume":"1","author":"D Launay","year":"2018","unstructured":"Launay D, Buchdahl A-L, B\u00e9rezn\u00e9 A, Hatron P-Y, Hachulla E, Mouthon L. Mycophenolate mofetil following cyclophosphamide in worsening systemic sclerosis-associated interstitial lung disease. J Scleroderma Relat Disord. 2018;1(2):234\u201340. https:\/\/doi.org\/10.5301\/jsrd.5000205.","journal-title":"J Scleroderma Relat Disord"},{"key":"2460_CR15","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s13075-015-0872-2","volume":"17","author":"D Khanna","year":"2015","unstructured":"Khanna D, Nagaraja V, Tseng C-H, Abtin F, Suh R, Kim G, et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther. 2015;17:372. https:\/\/doi.org\/10.1186\/s13075-015-0872-2.","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"2460_CR16","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1378\/chest.13-2626","volume":"146","author":"TA Winstone","year":"2014","unstructured":"Winstone TA, Assayag D, Wilcox PG, Dunne JV, Hague CJ, Leipsic J, et al. Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest. 2014;146(2):422\u201336. https:\/\/doi.org\/10.1378\/chest.13-2626.","journal-title":"Chest"},{"issue":"8","key":"2460_CR17","doi-asserted-by":"publisher","first-page":"e0181692","DOI":"10.1371\/journal.pone.0181692","volume":"12","author":"N Le Gouellec","year":"2017","unstructured":"Le Gouellec N, Duhamel A, Perez T, Hachulla A-L, Sobanski V, Faivre J-B, et al. Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. Plos One. 2017;12(8):e0181692. https:\/\/doi.org\/10.1371\/journal.pone.0181692.","journal-title":"Plos One"},{"issue":"6","key":"2460_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/BOR.0000000000000656","volume":"31","author":"B Skaug","year":"2019","unstructured":"Skaug B, Assassi S. Biomarkers in systemic sclerosis. Curr Opin Rheumatol. 2019;31(6):595\u2013602. https:\/\/doi.org\/10.1097\/BOR.0000000000000656.","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"2460_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1136\/thoraxjnl-2018-211779","volume":"74","author":"ND Weatherley","year":"2019","unstructured":"Weatherley ND, Eaden JA, Stewart NJ, Bartholmai BJ, Swift AJ, Bianchi SM, et al. Experimental and quantitative imaging techniques in interstitial lung disease. Thorax. 2019;74(6):611\u20139. https:\/\/doi.org\/10.1136\/thoraxjnl-2018-211779.","journal-title":"Thorax"},{"issue":"26","key":"2460_CR20","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis\u2013associated interstitial lung disease. N Engl J Med. 2019;380(26):2518\u201328.","journal-title":"N Engl J Med"},{"issue":"12","key":"2460_CR21","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2967\/jnumed.116.174946","volume":"57","author":"T Nobashi","year":"2016","unstructured":"Nobashi T, Kubo T, Nakamoto Y, Handa T, Koyasu S, Ishimori T, et al. FDG uptake in less affected lung field provides prognostic stratification in patients with interstitial lung disease. J Nucl Med. 2016;57(12):1899\u2013904.","journal-title":"J Nucl Med"},{"issue":"12","key":"2460_CR22","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/j.ejrad.2016.10.001","volume":"85","author":"V Jacquelin","year":"2016","unstructured":"Jacquelin V, Mekinian A, Brillet PY, Nunes H, Fain O, Valeyre D, et al. FDG-PET\/CT in the prediction of pulmonary function improvement in nonspecific interstitial pneumonia. A pilot study. Eur J Radiol. 2016;85(12):2200\u20135. https:\/\/doi.org\/10.1016\/j.ejrad.2016.10.001.","journal-title":"Eur J Radiol"},{"issue":"2","key":"2460_CR23","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00259-013-2514-8","volume":"41","author":"T Win","year":"2014","unstructured":"Win T, Thomas BA, Lambrou T, Hutton BF, Screaton NJ, Porter JC, et al. Areas of normal pulmonary parenchyma on HRCT exhibit increased FDG PET signal in IPF patients. Eur J Nucl Med Mol Imaging. 2014;41(2):337\u201342. https:\/\/doi.org\/10.1007\/s00259-013-2514-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2460_CR24","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1007\/s12350-016-0649-2","volume":"24","author":"E Redureau","year":"2017","unstructured":"Redureau E, Lairez O, Hitzel A, Pugnet G. Can positron emission tomography be useful to manage systemic sclerosis cardiac involvement? J Nucl Cardiol. 2017;24(5):1814\u20135. https:\/\/doi.org\/10.1007\/s12350-016-0649-2.","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"2460_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.4103\/0972-3919.178335","volume":"31","author":"M Vadrucci","year":"2016","unstructured":"Vadrucci M, Castellani M, Benti R. Active subcutaneous calcinosis demonstrated by fluorine-18 fluorodeoxyglucose positron emission tomography\/computed tomography in a case of limited. Indian J Nucl Med. 2016;31(2):154\u20135. https:\/\/doi.org\/10.4103\/0972-3919.178335.","journal-title":"Indian J Nucl Med"},{"issue":"4","key":"2460_CR26","doi-asserted-by":"publisher","first-page":"350","DOI":"10.4103\/0972-3919.164018","volume":"30","author":"K Oksuzoglu","year":"2015","unstructured":"Oksuzoglu K, Ozen G, Inanir S, Direskeneli RH. Flip-flop phenomenon in systemic sclerosis on fluorodeoxyglucose positron emission tomography\/computed tomography. Indian J Nucl Med. 2015;30(4):350\u20131. https:\/\/doi.org\/10.4103\/0972-3919.164018.","journal-title":"Indian J Nucl Med"},{"issue":"6","key":"2460_CR27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733\u201348. https:\/\/doi.org\/10.1164\/rccm.201308-1483ST.","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"2460_CR28","doi-asserted-by":"publisher","first-page":"7387","DOI":"10.1088\/0031-9155\/60\/18\/7387","volume":"60","author":"BF Holman","year":"2015","unstructured":"Holman BF, Cuplov V, Millner L, Hutton BF, Maher TM, Groves AM, et al. Improved correction for the tissue fraction effect in lung PET\/CT imaging. Phys Med Biol. 2015;60(18):7387\u2013402. https:\/\/doi.org\/10.1088\/0031-9155\/60\/18\/7387.","journal-title":"Phys Med Biol"},{"issue":"2","key":"2460_CR29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2967\/jnumed.116.184796","volume":"58","author":"DL Chen","year":"2017","unstructured":"Chen DL, Cheriyan J, Chilvers ER, Choudhury G, Coello C, Connell M, et al. Quantification of lung PET images: challenges and opportunities. J Nucl Med. 2017;58(2):201\u20137. https:\/\/doi.org\/10.2967\/jnumed.116.184796.","journal-title":"J Nucl Med"},{"issue":"10","key":"2460_CR30","doi-asserted-by":"publisher","first-page":"779","DOI":"10.4329\/wjr.v6.i10.779","volume":"6","author":"A Nambu","year":"2014","unstructured":"Nambu A, Ozawa K, Kobayashi N, Tago M. Imaging of community-acquired pneumonia: roles of imaging examinations, imaging diagnosis of specific pathogens and discrimination from noninfectious diseases. World J Radiol. 2014;6(10):779\u201393. https:\/\/doi.org\/10.4329\/wjr.v6.i10.779.","journal-title":"World J Radiol"},{"issue":"7","key":"2460_CR31","first-page":"1573","volume":"28","author":"EC LeRoy","year":"2001","unstructured":"LeRoy EC, Medsger TA. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28(7):1573\u20136.","journal-title":"J Rheumatol"},{"issue":"11","key":"2460_CR32","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F Hoogen","year":"2013","unstructured":"Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2013;65(11):2737\u201347. https:\/\/doi.org\/10.1002\/art.38098.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2460_CR33","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","volume":"177","author":"NSL Goh","year":"2008","unstructured":"Goh NSL, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, Maher TM, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177(11):1248\u201354. https:\/\/doi.org\/10.1164\/rccm.200706-877OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 5","key":"2460_CR34","doi-asserted-by":"publisher","first-page":"v59","DOI":"10.1093\/rheumatology\/ken271","volume":"47","author":"AU Wells","year":"2008","unstructured":"Wells AU. High-resolution computed tomography and scleroderma lung disease. Rheumatology (Oxford). 2008;47(Suppl 5):v59\u201361. https:\/\/doi.org\/10.1093\/rheumatology\/ken271.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2460_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2967\/jnumed.114.147421","volume":"56","author":"B Bondue","year":"2015","unstructured":"Bondue B, Sherer F, Van Simaeys G, Doumont G, Egrise D, Yakoub Y, et al. PET\/CT with 18F-FDG- and 18F-FBEM-labeled leukocytes for metabolic activity and leukocyte recruitment monitoring in a mouse model of pulmonary fibrosis. J Nucl Med. 2015;56(1):127\u201332. https:\/\/doi.org\/10.2967\/jnumed.114.147421.","journal-title":"J Nucl Med"},{"issue":"12","key":"2460_CR36","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1164\/rccm.201504-0780OC","volume":"192","author":"N Xie","year":"2015","unstructured":"Xie N, Tan Z, Banerjee S, Cui H, Ge J, Liu R-M, et al. Glycolytic reprogramming in myofibroblast differentiation and lung fibrosis. Am J Respir Crit Care Med. 2015;192(12):1462\u201374. https:\/\/doi.org\/10.1164\/rccm.201504-0780OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"2460_CR37","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1164\/rccm.201508-1699ED","volume":"192","author":"TM Maher","year":"2015","unstructured":"Maher TM. Aerobic glycolysis and the Warburg effect. An unexplored realm in the search for fibrosis therapies? Am J Respir Crit Care Med. 2015;192(12):1407\u20139. https:\/\/doi.org\/10.1164\/rccm.201508-1699ED.","journal-title":"Am J Respir Crit Care Med"},{"key":"2460_CR38","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ejrad.2016.09.014","volume":"86","author":"DL Chen","year":"2017","unstructured":"Chen DL, Schiebler ML, Goo JM, van Beek EJR. PET imaging approaches for inflammatory lung diseases: current concepts and future directions. Eur J Radiol. 2017;86:371\u20136. https:\/\/doi.org\/10.1016\/j.ejrad.2016.09.014.","journal-title":"Eur J Radiol"},{"issue":"1","key":"2460_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12931-017-0556-3","volume":"18","author":"A Justet","year":"2017","unstructured":"Justet A, Laurent-Bellue A, Thabut G, Dieudonn\u00e9 A, Debray M-P, Borie R, et al. [18F] FDG PET\/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis. Respir Res. 2017;18(1):74. https:\/\/doi.org\/10.1186\/s12931-017-0556-3.","journal-title":"Respir Res"},{"issue":"12","key":"2460_CR40","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.2967\/jnumed.115.163360","volume":"56","author":"Y Umeda","year":"2015","unstructured":"Umeda Y, Demura Y, Morikawa M, Anzai M, Kadowaki M, Ameshima S, et al. Prognostic value of dual-time-point 18F-FDG PET for idiopathic pulmonary fibrosis. J Nucl Med. 2015;56(12):1869\u201375. https:\/\/doi.org\/10.2967\/jnumed.115.163360.","journal-title":"J Nucl Med"},{"issue":"6","key":"2460_CR41","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/MNM.0000000000000083","volume":"35","author":"EYP Lee","year":"2014","unstructured":"Lee EYP, Wong CS, Fung SL, Yan PK, Ho JCM. SUV as an adjunct in evaluating disease activity in idiopathic pulmonary fibrosis - a pilot study. Nucl Med Commun. 2014;35(6):631\u20137. https:\/\/doi.org\/10.1097\/MNM.0000000000000083.","journal-title":"Nucl Med Commun"},{"issue":"3","key":"2460_CR42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s00259-011-1986-7","volume":"39","author":"T Win","year":"2012","unstructured":"Win T, Lambrou T, Hutton BF, Kayani I, Screaton NJ, Porter JC, et al. 18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials. Eur J Nucl Med Mol Imaging. 2012;39(3):521\u20138. https:\/\/doi.org\/10.1007\/s00259-011-1986-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"2460_CR43","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00259-009-1069-1","volume":"36","author":"Y Umeda","year":"2009","unstructured":"Umeda Y, Demura Y, Ishizaki T, Ameshima S, Miyamori I, Saito Y, et al. Dual-time-point 18F-FDG PET imaging for diagnosis of disease type and disease activity in patients with idiopathic interstitial pneumonia. Eur J Nucl Med Mol Imaging. 2009;36(7):1121\u201330. https:\/\/doi.org\/10.1007\/s00259-009-1069-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2460_CR44","doi-asserted-by":"publisher","unstructured":"Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J. Aetiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med. 2019. https:\/\/doi.org\/10.1164\/rccm.201903-0563CI.","DOI":"10.1164\/rccm.201903-0563CI"},{"key":"2460_CR45","doi-asserted-by":"publisher","unstructured":"Peelen DM, Zwezerijnen BGJC, Nossent EJ, Meijboom LJ, Hoekstra OS, Van der Laken CJ, et al. The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients. Rheumatology (Oxford). 2019. https:\/\/doi.org\/10.1093\/rheumatology\/kez483.","DOI":"10.1093\/rheumatology\/kez483"},{"issue":"4","key":"2460_CR46","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1136\/annrheumdis-2018-21337652","volume":"78","author":"S Bellando-Randone","year":"2019","unstructured":"Bellando-Randone S, Tartarelli L, Cavigli E, Tofani L, Bruni C, Lepri G, et al. 18F-fluorodeoxyglucose positron-emission tomography\/CT and lung involvement in systemic sclerosis. Ann Rheum Dis. 2019;78(4):577\u20138. https:\/\/doi.org\/10.1136\/annrheumdis-2018-21337652.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2460_CR47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S1095-0397(99)00016-3","volume":"2","author":"SM Larson","year":"1999","unstructured":"Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, et al. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in total lesion glycolysis. Clin Positron Imaging. 1999;2(3):159\u201371.","journal-title":"Clin Positron Imaging"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02460-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-021-02460-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02460-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,6]],"date-time":"2021-03-06T03:02:47Z","timestamp":1614999767000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02460-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,6]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2460"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02460-8","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,6]]},"assertion":[{"value":"13 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In accordance with the French legislation, ethical approbation and formal consent were not required. Data protecting complied with the requirements of the National Information Science and Liberties Commission (recorded as number DEC18-355).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}